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Abstract
Background: Hub proteins are connected through binding interactions to many other proteins. Smad3, a mediator of signal
transduction induced by transforming growth factor beta (TGF-b), serves as a hub protein for over 50 protein-protein
interactions. Different cellular responses mediated by Smad3 are the product of cell-type and context dependent Smad3-
nucleated protein complexes acting in concert. Our hypothesis is that perturbation of this spectrum of protein complexes
by mutation of single protein-binding hot-spots on Smad3 will have distinct consequences on Smad3-mediated responses.
Methodology/Principal Findings: We mutated 28 amino acids on the surface of the Smad3 MH2 domain and identified 22
Smad3 variants with reduced binding to subsets of 17 Smad3-binding proteins including Smad4, SARA, Ski, Smurf2 and
SIP1. Mutations defective in binding to Smad4, e.g., D408H, or defective in nucleocytoplasmic shuttling, e.g., W406A, were
compromised in modulating the expression levels of a Smad3-dependent reporter gene or six endogenous Smad3-
responsive genes: Mmp9, IL11, Tnfaip6, Fermt1, Olfm2 and Wnt11. However, the Smad3 mutants Y226A, Y297A, W326A,
K341A, and E267A had distinct differences on TGF-b signaling. For example, K341A and Y226A both reduced the Smad3-
mediated activation of the reporter gene by ,50% but K341A only reduced the TGF-b inducibilty of Olfm2 in contrast to
Y226A which reduced the TGF-b inducibility of all six endogenous genes as severely as the W406A mutation. E267A had
increased protein binding but reduced TGF-b inducibility because it caused higher basal levels of expression. Y297A had
increased TGF-b inducibility because it caused lower Smad3-induced basal levels of gene expression.
Conclusions/Significance: Mutations in protein binding hot-spots on Smad3 reduced the binding to different subsets of
interacting proteins and caused a range of quantitative changes in the expression of genes induced by Smad3. This
approach should be useful for unraveling which Smad3 protein complexes are critical for specific biological responses.
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Introduction
Transient protein-protein interactions are a ubiquitous molecular
mechanism for regulating virtually every cellular function and for
crosstalk between signaling pathways [1,2]. Protein interaction
mapping has identified certain proteins, called hub proteins, that
are connected through binding interactions to many other proteins
[3,4,5]. Dissecting the functional importance of the many different
and potentially overlapping binding sites on a hub protein is a
challenge. For example, Smad3 is a key mediator of the signal
transduction processes induced by transforming growth factor beta
(TGF-b) that serves as a hub protein for many different protein-
binding partners [6]. TGF-b plays a prominent role in regulating a
variety of cellular functions including cell migration, cell proliferation,
apoptosis, differentiation, immunosuppression, inflammation, tumor-
suppression, and angiogenesis [7,8]. Elevated TGF-b signaling also
has been associated with several disease states including metastasis
and immune evasion by cancer cells [9,10] and fibrosis in many
tissues including skin, lung and kidney [11,12,13]. The specific
cellular responses to TGF-b are context dependent and vary
according to the cell type, the cellular environment, and the activity
of other signaling pathways [14]. The broad diversity of cellular
responses to TGF-b is generated primarily through two mechanisms:
protein-protein interactions between the TGF-b-activated Smad2,
Smad3 and Smad4 proteins and over 50 transcriptional activator and
repressorproteins, and parallel activation byTGF-b of several Smad-
independent signaling pathways including the Ras-MAPK pathway
and the RhoA/ROCK/cofilin pathway [15,16,17].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25021Smad2 and Smad3, the receptor-regulated or R-Smads, are
phosphorylated in response to TGF-b binding to its Type II and
Type I receptor serine kinases [8,18,19]. The phosphorylated
Smad2 or Smad3 MH2 domains can assemble into homomeric
trimers but the preferred structure is a heterotrimer consisting of
two R-Smads and one Smad4 [20,21,22,23]. Although very
similar in structure and primary amino acid sequence, Smad2 and
Smad3 affect distinct cellular genes [24,25,26]. For example,
Smad3 has been shown to mediate epithelial to mesenchymal
transition induced by TGF-b in mouse mammary epithelial cells
including changes in cell morphology, cell-cell junctions, increased
MMP9 expression, reduced proliferation and increased apoptosis
[27]. Smad3 also mediated the invasive behavior of a malignant
subclone of MCF10A1 human breast cancer cells, in part through
induction of MMP2 and MMP9 [28]. Recently, Smad3 mutations
have been associated with an inherited autosomal dominant aortic
aneurysm syndrome [29]. The specific involvement of Smad3 in
several disease-related phenotypes regulated by TGF-b led us to
focus on perturbing Smad3 protein-protein interactions in order to
better understand its molecular mechanisms of action.
Smad3 has a similar structure to other Smad proteins including
an N-terminal globular domain with DNA binding activity (the
MH1 domain), a central linker region with regulatory sites, and a
C-terminal globular domain (the MH2 domain) with transcrip-
tional regulatory activity [30]. The MH2 domains have a central b
sandwich, with a conserved three-helix bundle (H3, H4, and H5)
on one end and a conserved loop-helix region (L1, L2, L3, and
H1) on the other end [21]; these two surfaces form the Smad-
Smad binding interface in the Smad trimer. Although the Smad
MH2 domain is able to bind many different Smad-interacting
proteins, these interacting proteins do not share a conserved
sequence motif that binds to Smad MH2. Structural analyses of R-
Smad co-crystals have defined binding sites for just three R-Smad
protein-protein interactions: the Smad-Smad trimer interface
[20,21,22,23], Smad4 binding to a peptide from Ski [31], and
the hydrophobic groove on Smad2 that binds to a peptide from
SARA [22,32,33].
We have generated a series of Smad3 variants that are
selectively compromised in binding a subset of Smad3-interacting
proteins by engineering mutations in one or more amino acids on
the surface of Smad3 at putative protein-binding ‘‘hot-spots’’
[34,35,36,37]. Hot-spots may be clustered on the protein surface,
producing hot regions; the hot-spots within a hot region may
exhibit cooperative binding to a protein ligand [38,39]. Different
hot regions are used to bind to different partners in a hub protein
[4]. Amino acids were selected for mutation based on their
apparent role in mediating protein binding in one of the known
Smad co-crystal structures, by their location on the surface of the
Smad3 MH2 domain crystal structure and enrichment in hot-spots
in other proteins [35,40,41,42,43], or because of previous
mutagenesis studies that showed reductions in Smad3 or Smad2
protein binding. For example, mutations in the alpha-helix2
region within the hydrophobic groove were previously shown to
reduce the binding interaction with the Smad-binding domains
from the Xenopus FoxH1 and Mixer transcription factors [44,45].
Results are presented for 28 variants distributed across three
different regions on the surface of Smad3: the interfaces mediating
binding to Smad4, the hydrophobic corridor defined by the
Smad2-SARA co-crystal structure, and the cap region defined by
its role in binding to Ski. We characterized the Smad3 variants for
binding to a panel of candidate Smad3-binding proteins and
peptides all of which had been shown to bind directly to Smad3 in
previous studies. Most of the Smad3 variants exhibited reduced
binding to one or more of the seventeen Smad3-binding proteins
or peptides tested, consistent with the mutated amino acids
contributing significantly to one or more binding interactions, i.e,
a hot-spot, but also consistent with the presence of different amino
acids on Smad3 acting as hot-spots for binding to different protein
or peptide ligands. The functional consequences of the mutations
were assayed by quantifying their ability to reconstitute TGF-b-
induced, Smad3-dependent reporter gene activation in Smad3-
deficient JEG-3 cells [46] and by their affects on the TGF-b-
inducibilty of six Smad3-regulated genes in C2C12 myoblasts.
E267A increased protein binding and had the unique property of
reducing TGF-b inducibility by inducing high basal expression
levels of the six endogenous genes. Y297A fully rescued reporter
gene expression but mediated reduced expression of the six
endogenous genes while unexpectedly increasing the fold activa-
tion of these genes by TGF-b because it induced lower basal
expression levels of the genes than did wild-type Smad3. Y226A
reduced reporter gene expression by only 50% but was
comparable to W406A and V356R in its severe reduction of the
TGF-b-inducibilty of the six endogenous genes. As with Y226A,
K341A reduced reporter gene activation by about 50% but in
contrast to Y226A it only had minimal effects on the six
endogenous genes except for reducing expression levels of Olfm2.
The double mutant Q322A/Y324A was as severe as W406A in
reducing the ability of Smad3 to increase the expression of the six
endogenous genes but retained more function than W406A in
mediating the reporter gene activation and in the TGF-b-
inducibilty of the six Smad3-regulated genes in C2C12 myoblasts.
Results
Amino acids predicted by the crystal structure to be on the
surface of the Smad3 MH2 domain were mutated, typically to
alanine (Figure 1). These amino acids were chosen based on prior
studies implicating them in mediating Smad3 or Smad2 protein
interactions, or because they are among the group of amino acids
(R, W, Y) enriched in mediating protein-protein interaction hot-
spots in other proteins [35]. Prior structural and mutational studies
on Smad2 were used to guide our mutational analysis of Smad3
because Smad3 and Smad2 MH2 domains share 92% identity at
the primary amino acid sequence level and similar 3D structures
[23]. Mutations were made on the triple helix and loop-helix
interfaces, respectively, that mediate Smad3 binding to Smad4 or
Smad2 in the heterotrimeric structure formed upon phosphory-
lation of Smad3 (Figure 1A) [20,21,22,23]. Most of the mutations
were made on the opposite side of Smad3 that includes the
hydrophobic corridor defined by the co-crystal of the SARA
Smad-binding domain and Smad2 [32](Figure 1B). Mutations
were also made in a region at the top of the Smad trimer toroid
previously shown to be involved in binding to Ski [47](Figure 1B).
T h ee f f e c to fa n yo n em u t a t i o no rp a i ro fm u t a t i o n so nS m a d 3
protein binding was quantified using a modification of the LUMIER
(luminescence-based mammalian interactome mapping) assay orig-
inally described by Dr. Jeffery Wrana and colleagues [48]. The full-
length mutant Smad3 proteins were expressed as Renilla luciferase
fusion proteins in HEK-293 cells together with a Flag-tagged Smad3
binding partner and the constitutively activated Alk5 Type I receptor
kinase that phosphorylates Smad3. The Flag-tagged Smad-binding
partners were expressed either as full-length proteins or as Smad-
binding domains displayed on the surface of a Thioredoxin (Trx)
scaffold. We have previously described the use of the Thioredoxin
scaffold to display Smad-binding domains [49,50,51]. The Flag-
tagged protein was recovered from cell lysates on anti-Flag antibody
coated 96-well plates and the amount of co-immunoprecipitated
Smad3 was measured by Renilla luciferase activity. Co-expression of
Protein-Binding Hot-Spot Mutations on Smad3
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to Flag-Smad4 (Table1), confirming that the binding assay accurately
detected the increased binding of Smad3 to Smad4 expected upon
phosphorylation of Smad3. In contrast, Smad3 binding to the Smad-
binding domain from SARA was not significantly affected by co-
transfection with the activated receptor kinase (Table 1), consistent
with the ability of the SARA Smad-binding domain to bind
unphosphorylated or phosphorylated Smad3 [51].
Mutations known to disrupt Smad3 binding interactions
are detected in the LUMIER assay and exhibit selective
disruption of a subset of binding interactions
Retention of control levels of binding to one or more Smad-
binding proteins by the mutant Smad3 proteins was used as the
criteria to indicate that a specific mutation was exerting a local
effect and not causing a general disruption of Smad3 MH2 protein
structure/folding. Mutations in amino acids that reduced co-
immunoprecipitation with all of the Smad-binding proteins tested
(F303A, R295A and R240A) were likely to have affected the
overall structure of the MH2 domain and were not included in
further analyses. Reduced binding by a Smad3 mutant to any
single Smad-binding protein, relative to the binding of wild-type
Smad3, also could be an artifact of low expression of the mutant
protein. To control for this, total Renilla luciferase activity was
measured in each transfected cell lysate as a surrogate measure for
the level of Renilla-Smad fusion protein. Co-immunoprecipitation
data is only reported for experiments where the level of luciferase
activity of the mutant Renilla-Smad3 fusion protein was within
Figure 1. Mutations on the Smad3 MH2 domain. (A) A model of the Smad3 MH2 domain showing the surfaces including the triple helix and
loop helix interfaces that mediate binding to Smad4 [23] with mutated amino acids highlighted. (B) A model of the Smad3 MH2 domain rotated 180u
from the view in panel A, showing the surface with the hydrophobic corridor that binds to SARA [32] with mutated amino acids highlighted:
tryptophan in hot-pink; aspartic acid, glutamic acid and glutamine in red; arginine and lysine in blue; tyrosine and serine in green; and proline, valine,
and leucine in yellow.
doi:10.1371/journal.pone.0025021.g001
Table 1. The luminescence-based mammalian interactome assay (LUMIER) detects reductions in subsets of Smad3 protein
interactions due to mutations in Smad3 or the absence of Smad3 phosphorylation.
Smad3 (WT or mutant) Percent binding relative to the binding by phosphorylated wild-type Smad3
Smad4 SARA Smurf2 Ski
FL aa665–721 aa252–330 aa2–56
Smad3 WT+Alk5 100 100 100 100
Smad3 WT, No Alk5 6 (1) 78 (26) Nd nd
D408H 3 (1) 125 (45) 23 (12) 3 (1)
Del-PPGY (182–185) 120 (15) 129 (16) 3 (1) 160 (50)
Y297A 181 (42) 8 (3) 119 (20) 1 (1)
QPSMT/SE* 132 (18) 61 (26) 86 (29) 4 (1)
Binding between wild-type or mutant Renilla-Smad3 fusion proteins and four different Flag epitope-tagged Smad-binding proteins was quantified by pull-down of
protein complexes from cell lysates in anti-Flag antibody-coated 96-well plates and measuring the amount of luciferase activity per well in a luminometer. The luciferase
counts were normalized to the number of counts recovered with phosphorylated wild-type Smad3 (100%). All of the Smad3 mutant proteins were co-expressed with
the constitutively active Alk5. The average of the data from at least four independent transfections is shown. Total Renilla luciferase activity was measured in each
transfected cell lysate as a surrogate measure for the level of Renilla-Smad fusion protein; data is only reported for experiments where the level of each Renilla-Smad3
mutant was within two-fold of the level of the Renilla-Smad3 wild type protein in the same experiment. FL indicates that the full-length Smad4 protein was used. The
amino acids comprising the SARA [32], Smurf2 [52] and Ski [22] Smad3-binding motifs that were expressed on the Flag-epitope tagged thioredoxin scaffold are
indicated below each gene. The reduced binding interactions of the Smad3 mutants D408H and Y297A to the Ski Smad-binding domain are consistent with previous
studies using different assay methods [22]. Standard deviations are indicated in parenthesis. Not determined (nd).
*The Smad3 QPSMT/SE mutant has residues 252–256 and 266–267 changed to the Smad1 equivalent amino acids (STSVL/NKN) [47].
doi:10.1371/journal.pone.0025021.t001
Protein-Binding Hot-Spot Mutations on Smad3
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Renilla-Smad3 fusion protein in the same experiment.
Four mutant Smad3 proteins each previously reported to be
defective in binding to one Smad-binding partner were co-
expressed with Smad4 or one of three different Smad-binding
peptides to determine if the assay was sensitive enough to detect
perturbation of binding by mutations in Smad3 (Table 1). The
three Smad-binding peptides were from SARA [32], Smurf2 [52]
and Ski [22,53]. Mutation of Smad3 D408 to histidine (D408H)
greatly reduced binding to Smad4, consistent with previous studies
in which mutation of D408 in Smad3, or the corresponding
aspartic acid in Smad2 or Smad4, resulted in defects in Smad
complex formation and in TGF-b-dependent phosphorylation of
the mutant R-Smad [54,55,56,57]. Smad3 D408H retained wild-
type levels of binding to the SARA Smad-binding peptide,
however, binding to the Smad-binding peptides from Smurf2
and Ski was significantly reduced (Table 1); the reduction in
binding to Ski was consistent with prior studies on this mutation
[22]. Deletion of the PPGY motif in the Smad3 linker region that
mediates the interaction between R-Smads and the Smurf2 WW
domains [52,58] reduced binding specifically to the Smad binding
domain from Smurf2 (Table 1). Mutation of Y297 to alanine
reduced binding to the SARA Smad-binding domain, as predicted
by the co-crystal structure [32], and to the Smad-binding domain
from Ski [22] but it did not reduce binding to Smad4 or to the
Smad-binding peptide from Smurf2 (Table 1). Smad3 with the
STSVL of Smad1 in place of QPSMT of Smad3 amino acids 252–
256 and the NKN residues of Smad1 in place of the SE of Smad3
amino acids 266–267 exhibited decreased binding to the Smad-
binding peptide from Ski as reported in previous studies [47], but
retained binding to Smad4 and the Smurf2 Smad-binding peptide
(Table 1). Since the assay was able to detect selective perturbations
on protein binding imparted by the control mutations in Table 1,
it was used to examine a larger number of mutations and
interacting proteins.
Smad3 mutations that reduce binding to Smad4 also
reduce other protein-protein interactions
The six mutations in Smad3 shown in Figure 1A reduced
binding to Smad4 (Table 2). With the exception of R292, these
have all been implicated by the co-crystal structures in mediating
the Smad3-Smad4 interaction [21,23]. D408 and R268 form salt
bridges between Smad3 and the corresponding arginine or
aspartic acid, respectively, on Smad4 or an R-Smad in the
heterotrimer. Smad3 R243 participates in a charge-charge
interaction with E337 on Smad4 and the position of Y238 in
the structure indicates that it could be involved in the proper
positioning of R243. All six mutations also reduced binding to
Smad3, but retained binding to the SARA Smad-binding domain
and full length SARA [59]. The Smad3 D408H mutation also
retained near wild-type levels of binding to the xFoxH1, SRF and
ATF3 Smad-binding peptides, MyoD, MEF2C, and Axin (Table
S1). All six mutations unexpectedly reduced binding to the Smad-
binding domains from Smurf2 and SIP1 (Table 2). Binding to the
Ski Smad-binding peptide was greatly reduced by the six
mutations, but this was consistent with previous reports in which
binding of the Ski peptide was reduced in R-Smad mutants unable
to form hetero-trimeric complexes [22]. The W274E mutation of
full-length Ski, which reduces binding of Ski to Smad4 [53] was
used to limit the binding interaction detected in the co-
immunoprecipitation assay to Smad3-Ski. Binding of the
SkiW274E protein to Smad3 also was reduced by the six
mutations but there was significantly more binding to full-length
Ski than to the Ski Smad-binding peptide. The binding behavior
of all six mutants was highly correlated; the Spearman’s rank
correlation coefficients were from 0.66 to 0.097 and all pairwise
correlations were significant (p,0.05).
Smad3 mutations that retain binding to Smad4 are
defective in binding to other partners
The co-crystal structure of Smad2 and the SARA Smad-binding
domain defined a hydrophobic corridor on the surface of Smad
opposite the interfaces mediating binding to Smad4 [32]
(Figure 1B). The Smad3 mutations in Table 3 fall in or near this
hydrophobic corridor. These fourteen Smad3 mutations retained
binding to Smad4 and Smad3 but exhibited altered binding to
other proteins tested (Table 3). All of the mutations had wild-type
or greater binding to the Smad-binding domain from Smurf2, in
contrast to the deletion of the PPGY motif that reduced binding to
the Smurf2 Smad-binding peptide (Table 3). The mutations in the
region of the hydrophobic corridor near the Smad3 alpha helix 2,
which is on the lower left side in Figure 1B, Q322A/Y324A and
W326A decreased binding to SARA (Table 3). These amino acids
were previously reported to be involved in binding to SARA [32]
and are also involved in binding a motif from the Xenopus proteins
FoxH1, Mixer and Milk [44] (Table S1). However, these
mutations did not reduce binding to the Smad-binding domains
from Ski or SIP1 (Table 3).
Four mutations were created in the beta-8/beta-9 region of
Smad3, which is on the left side in Figure 1B: P335A/P336A,
C338A, L340A, and K341A [63] (Figure 1B and Table 3). The
P335A/P336A double mutant was selective for only decreasing
binding of the SARA Smad-binding domain and full-length SARA
of the proteins tested. Given that Smad3 binds to over 50 proteins,
it seems likely that this double mutant will be defective in binding
to other proteins in addition to SARA, but we do not know the
identity of these at this time. Similarly, Smad3 C338A was
selective for a partial but significant reduction in binding to the
SIP1 Smad-binding domain. The L340A mutation reduced
binding to SARA and to SkiW274E, but not to the Smad-binding
aa2-56 peptide from Ski. The K341A mutation had broader
effects on protein binding, reducing binding to the Smad-binding
domains from SARA, Ski and SIP1 as well as the full-length
proteins SARA and SkiW274E. The Smad3 K341A mutation
maintained substantial binding interactions with several other
proteins tested (Table S1). Double mutations of the corresponding
cysteine and leucine or leucine and lysine in Smad2 were reported
to interfere with Smad2 nucleocytoplasmic shuttling [63].
A Smad1/3 chimeric protein expressing the NKN/STSVL
residues of Smad1 in place of the SE/QPSMT amino acids in
Smad3, exhibited decreased binding to Ski [47]. Each of the six
amino acids in this region, which is on the top of the structure
shown in Figure 1B, that are different between Smad1 and Smad3
were mutated to alanine in Smad3. None of the mutations had
decreased binding to Smad3 or Smad4 (Table 3 and Table S2). Of
these six mutations, only Smad3 S254A decreased Smad3 binding
to the Ski Smad-binding domain (Table 3). Unexpectedly, E267A
had increased binding to Smad3, Smad4, and the Smad-binding
domains from Ski and Smurf2 (Table 3). An adjacent mutation,
Y297A [22] (Figure 1B), caused reduced binding to the Ski Smad-
binding domain and SkiW274E, but also caused significant
reductions in binding to the SARA Smad-binding domain and
SARA (Table 3).
Five mutations were made in the region of the hydrophobic
corridor formed in part by the triple helix bundle, located on the
right side of Figure 1B: Y298A, V224A [22,64], Y226A [22,64],
V356R [63,65] and W406A [22,63,64,65]. The Y298A mutation
caused a significant reduction specifically in binding to the SIP1
Protein-Binding Hot-Spot Mutations on Smad3
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differential effects on interactions with other Smad-binding proteins.
Smad3
Mutants Percent binding to Smad3 mutants relative to the binding to wild-type Smad3 (100%)
Smad4 Smad3 SARA SARA Smurf2 Ski SkiW274E Sip1
FL FL 665–721 FL 252–330 2–56 FL 315–487
D408H 3 (1) 30 (5) 125 (45) 168 (52) 23 (12) 3 (1) 31 (7) 41 (9)
R268A 18 (8) 27 (8) 116 (14) 159 (40) 21 (9) 2 (2) 62 (28) 13 (10)
Y238A 27 (9) 24 (2) 74 (4) 162 (50) 28 (9) 2 (1) 44 (3) 15 (2)
R243A 20 (14) 46 (1) 72 (33) 181 (24) 19 (3) 3 (1) 72 (16) 28 (3)
R292A 49 (16) 49 (16) 78 (31) 120 (33) 31 (16) 4 (1) 59 (11) 32 (2)
Y384A 19 (9) 28 (6) 119 (44) 178 (33) 24 (11) 3 (1) 53 (6) 41 (6)
Binding between wild-type or mutant Renilla-Smad3 fusion proteins and eight different Flag epitope-tagged Smad-binding proteins was quantified by pull-down of
protein complexes from cell lysates and detection of the Renilla luciferase activity per well. The Renilla luciferase counts were normalized to the number of counts
recovered with phosphorylated wild-type Smad3 (100%). The proteins were co-expressed with the constitutively active Alk5. The average of the data from at least four
independent transfections is shown. Total Renilla luciferase activity was measured in each transfected cell lysate as a surrogate measure for the level of Renilla-Smad
fusion protein; data is only reported for experiments where the level of each Renilla-Smad3 mutant was within two-fold of the level of the Renilla-Smad3 wild type
protein in the same experiment. FL indicates that the full-length protein was used, e.g., full-length SARA [59]. The amino acids comprising the SARA [32], Smurf2 [52], Ski
[22], and Sip1 [94] Smad3-binding motifs expressed on the Flag-epitope tagged thioredoxin scaffold are indicated below each gene. Standard deviations are indicated
in parenthesis.
doi:10.1371/journal.pone.0025021.t002
Table 3. Mutations on the Smad3 MH2 interface that mediates binding to SARA [32] retain binding to Smad4 and Smad3 but have
differential effects on interactions with other Smad-binding proteins including, in some cases, increased binding.
Smad3 Mutants Percent binding to Smad3 mutants relative to the binding to wild-type Smad3 (100%)
Smad4 Smad3 SARA SARA Smurf2 Ski SkiW274E Sip1
FL FL 665–721 FL 252–330 2–56 FL 315–487
Q322A/Y324A 124 (6) 143 (12) 3 (1) 12 (5) 308 (44) 237 (42) 100 (22) 162 (29)
W326A 194 (20) 159 (46) 4 (3) 13 (6) 653 (198) 292 (73) 88 (15) 319 (38)
P335A/P336A 309 (59) 109 (9) 2 (1) 16 (5) 255 (79) 356 (55) 118 (28) 123 (24)
C338A 125 (38) 100 (17) 94 (11) 136 (23) 153 (21) 188 (32) 111 (42) 44 (11)
L340A 181 (42) 99 (31) 12 (3) 58 (10) 259 (51) 194 (60) 57 (19) 159 (16)
K341A 275 (60) 95 (18) 4 (2) 29 (4) 130 (30) 27 (8) 55 (15) 66 (8)
S254A 101 (46) 105 (10) 103 (32) 154 (34) 113 (28) 10 (5) 78 (25) 128 (103)
E267A 458 (399) 222 (12) 81 (8) 82 (20) 379 (71) 1152 (374) 137(9) 88 (41)
Y297A 181 (42) 82 (10) 8 (3) 38 (11) 119 (20) 1 (1) 29 (10) 80 (7)
Y298A 120 (13) 113 (21) 73 (26) 150 (47) 144 (7) 271 (73) 121 (19) 33 (19)
V224A 122 (13) 118 (26) 21 (9) 42 (5) 320 (59) 524 (84) 212 (63) 339 (114)
Y226A 110 (9) 161 (26) 3 (1) 32 (10) 365 (26) 32 (17) 89 (14) 7 (6)
V356R 233 (55) 275 (87) 1 (1) 16 (12) 468 (70) 2 (8) 30 (4) 7 (7)
W406A 109 (8) 564 (89) 1 (1) 12 (3) 1327 (151) 5 (1) 21 (7) 15 (1)
Del-PPGY 120 (15) 86 (15) 129 (16) 158 (69) 3 (1) 160 (50) 83 (18) 200 (13)
Binding between wild-type or mutant Renilla-Smad3 fusion proteins and eight different Flag epitope-tagged Smad-binding proteins was quantified by pull-down of
protein complexes from cell lysates and detection of the Renilla luciferase activity per well. The Renilla luciferase counts were normalized to the number of counts
recovered with phosphorylated wild-type Smad3 (100%). The proteins were co-expressed with the constitutively active Alk5. The average of the data from at least four
independent transfections is shown. Total Renilla luciferase activity was measured in each transfected cell lysate as a surrogate measure for the level of Renilla-Smad
fusion protein; data is only reported for experiments where the level of each Renilla-Smad3 mutant was within two-fold of the level of the Renilla-Smad3 wild type
protein in the same experiment. FL indicates that the full-length protein was used. The amino acids comprising the SARA [32], Smurf2 [52], Ski [22], and Sip1 [94] Smad3-
binding motifs expressed on the Flag-epitope tagged thioredoxin scaffold are indicated below each gene. The Smad3 Del-PPGY (182–185) mutation is included in the
last row although it resides in the Smad3 linker region and not in the MH2 domain. Reduced binding interactions to the Smad interaction motif from Ski by W406A,
Y297A and Y226A are consistent with previous studies on this protein interaction that used size exclusion chromatography with purified proteins [22,64]. Standard
deviations are indicated in parenthesis.
doi:10.1371/journal.pone.0025021.t003
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reduced binding to the SARA Smad-binding domain and SARA.
The Y226A, V356R and W406A mutations reduced binding to
full length SARA as well as the SARA, Ski and SIP1 Smad binding
domains (Table 3). The Smad3 mutations V356R and W406A
(and the corresponding mutations in Smad2) also are known to
interfere with Smad2 nucleocytoplasmic shuttling [63,65]. V224A,
Y226A, V356R and W406A Smad3 variants exhibited near wild-
type levels of binding to MyoD, MEF2C, Axin and the SRF
Smad-binding domain (Table S1).
Transcriptional activation of a TGF-b-responsive, Smad3-
dependent reporter gene is compromised by some
Smad3 mutations
The Smad3 variants were expressed in the Smad3-deficient
JEG-3 choriocarcinoma cell line [46] together with a Smad3-
dependent luciferase reporter plasmid. Expression of wild-type
Smad3 and several of the mutant Smad3 proteins restored TGF-b
activation of the reporter gene (Figure 2). The D408H mutant
protein and the other mutants shown in Table 1 that had reduced
Smad4 binding, all failed to restore signaling, consistent with the
canonical Smad pathway in which Smad3 (and Smad2) form
heterotrimers with Smad4 to activate or repress target gene
expression. Of the six mutations in Table 2, the R292A mutant
had the greatest binding to Smad4 and the highest rescue of
reporter gene expression (Figure 2). As the mutations are listed in
Figure 2 by their location on the structure (Figure 1), note the
uniform structure-activity response of mutations on the Smad4-
binding interface (D408 to Y384) versus the dispersed effect of
mutations elsewhere on the Smad3 surface. For the Smad3
variants that bound to Smad4 (Table 3), some had wild-type levels
of transcriptional activity on the reporter gene, while several
others, Q322A/Y324A, K341A, Y298A, Y226A, V356R and
W406A, were compromised in their ability to activate transcrip-
tion from the reporter gene. In terms of structure-activity
relationships, Y324 and K341 may define a motif that appears
to functionally important, although several other amino acids in
this region, e.g., L340 and W326, were not required for reporter
gene activiation. A second functional region may be defined by
Y226, V356 and W406, although V224, which resides right in the
middle of the other three, was not required. A previous report
showed that the Smad3 mutants V356R and W406A failed to
restore TGF-b-induced reported gene activity in HaCaT human
kerationcytes, consistent with the defects these mutations cause in
Smad3 nucleocytoplasmic shuttling [65]. The other mutations
may reduce the binding of Smad3 to one or more Smad-binding
proteins such that the reporter gene is not fully induced by TGF-b
in the JEG-3 cells, however these studies do not identify which
Smad3-binding protein or proteins are needed for full reporter
gene activation in the JEG-3 cells.
The ability of each Smad3 mutant to rescue the reporter gene
was correlated with the protein binding data in Tables 2 and 3
using Kendall’s rank correlation analysis (Table 4). As expected,
the analyses revealed significant correlation of the Smad3 mutants
binding to Smad3 and Smad4 and correlation of the Smad3
mutants binding to either the peptide binding motif or full length
proteins of SARA or SKI. Unexpectedly, the binding of the panel
of hot-spot mutations correlated significantly for binding to both
Figure 2. Rescue of TGF-b signaling in Smad3 deficient JEG-3 cells by wild-type and mutant Renilla-Smad3 fusion proteins. JEG-3
cells were transfected with plasmids for the Smad3-dependent firefly luciferase reporter gene SBE12-luciferase [97], the pCMV5 Renilla luciferase
plasmid encoding wild-type or mutant Smad3 and a plasmid encoding beta-galactosidase that was used to normalize for differences in transfection
efficiency. After 24 hours of 100 pM TGF-b, cell lysates were analyzed for luciferase and beta-galactosidase activities. Total Renilla luciferase activity
was measured in each transfected cell lysate to confirm comparable expression levels of Renilla-Smad3 fusion proteins. The TGF-b-induced firefly
luciferase activity for each mutant was normalized to the activity provided by wild-type Smad3 (100%). The average of the data from a minimum of
six independent transfections with each Smad3 variant are shown. The levels of reporter gene expression for cells transfected with wild-type and
mutant Smad3 were compared using a permutation test that combined the results of the replicate experiments. For mutants with reduced reporter
gene activity, P-values (corrected for multiple comparisons) less than 0.02 (*) and less than 0.001 (**) are indicated. The activity observed with Smad3
D408H was indistinguishable from the activity of JEG-3 cells without any exogenous Smad3. Most of the Smad3 mutants that altered binding to
Smad4 (Table 2) provided reduced rescue of Smad3 signaling. Some of the mutations that retained Smad4 binding also provided reduced rescue of
Smad3 signaling but other Smad3 mutations that had specific defects in protein binding (Table 3) were as effective as wild-type Smad3 for restoring
signaling in the JEG-3 cells.
doi:10.1371/journal.pone.0025021.g002
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the Smad3 inhibitor SKI (Table 4). Significant negative correla-
tions indicated that hot-spots reducing binding to one of these
Smad3 binding partners correlated with increased binding to
another Smad3 binding partner. As expected, rescue of the
Smad3-dependent reporter gene activation correlated with
binding to Smad4, consistent with the canonical Smad3 signaling
pathway in which a Smad3-Smad4 heterotrimer activates
transcription. Rescue also significantly correlated with how the
entire panel of hot-spot mutations affected binding to the SIP1
peptide or SKI274E. It is important to note that these results do
not imply that SIP1 or SKI are involved in activating the Smad3-
dependent reporter gene in JEG3 cells. SKI, for example, is a
negative regulator of Smad3 signaling, not a positive co-factor.
Rather, the results imply that the constellation of hot spots on
Smad3 involved in optimal binding to the SIP1 peptide and to
SKI are also involved in binding to un-identified co-factors in the
JEG3 cells that are needed for optimal Smad3-dependent
activation of the luciferase reporter gene. In contrast, rescue of
the reporter gene did not correlate with how the whole panel of
hot-spot mutations affected binding to Smurf2 peptide or to
SARA, even though there were individual mutations, e.g., Smad3
W406A, that reduced both binding to SARA (Table 3) and rescue
of the reporter gene (Figure 2). The different conclusions reached
by correlation analysis of the entire panel of hot-spot mutations
versus the properties of a single mutation, Smad3W406A,
indicates that correlation analysis of the protein binding and
functional activity of a large panel of hot-spot mutations may be a
powerful approach to identify which endogenous Smad3 binding
proteins are involved in specific gene expression responses.
Smad3 variants exhibit quantitative differences in the
TGF-b inducibilty of six Smad3-regulated genes in C2C12
cells
To examine whether the individual Smad3 mutations modify
the ability of the protein to mediate TGF-b induction of
endogenous genes, myc-epitope-tagged Smad3 variants or wild-
type protein were over-expressed from a retroviral vector in
populations of infected C2C12 myoblasts. Levels of wild-type and
mutant Smad3 proteins were quantified in two independent
replicates (A and B) of infected C2C12 cell populations by
Table 4. Correlation analysis of Smad3 mutant protein binding assays and rescue of the Smad3-dependent reporter gene assay.
Sample1 Sample2 tau P-value FDR
Smad3 Smad4 0.4 0.005045 0.01261
TrxSki SkiW274E 0.64 0.0001 0.0002
SARA TrxSARA 0.54 0.0001 0.0016
TrxSki TrxSIP1 0.48 0.0008 0.0036
SARA TrxSmurf2 20.46 0.0012 0.0048
Smad4 TrxSARA 20.32 0.0247 0.0464
RESCUE Smad4 0.46 0.0013 0.0044
RESCUE TrxSIP1 0.56 0.0001 0.0014
RESCUE SkiW274E 0.4233 0.003008 0.008461
RESCUE SARA 20.003333 0.9814 0.9814
RESCUE TrxSmurf2 0.2267 0.1123 0.1742
Sample1 Sample2 tau P-value FDR
Smad3 Smad4 0.4 0.005 0.013
Ski 2–56 SkiW274E 0.64 0.0001 0.0002
SARA SARA 665–721 0.54 0.0001 0.0016
Ski 2–56 SIP1 315–487 0.48 0.0008 0.0036
SARA Smurf2 252–330 20.46 0.0012 0.0048
Smad4 SARA 665–721 20.32 0.025 0.046
RESCUE Smad4 0.46 0.0013 0.0044
RESCUE SIP1 315–487 0.56 0.0001 0.0014
RESCUE SkiW274E 0.42 0.003 0.0085
RESCUE SARA 20.003 0.98 0.98
RESCUE Smurf2 252–330 0.23 0.11 0.17
Protein binding data from Tables 2 and 3 and reporter gene activation data (RESCUE) from Table 2 were tested pairwise for their ability to correlate based on each
sample’s results with all of the Smad3 mutants using Kendall’s rank correlation analysis. The data were analyzed using Mstat 5.4. Tau is the correlation coefficient. The p-
value is shown with the false discovery rate (FDR) correction, which accounts for the multiple comparisons. The first three rows of data confirm expected results that, for
the panel of hot-spot mutations examined, binding to Smad3 and Smad4 correlate, binding to full length SkiW274E and the Ski peptide correlate, and binding to full
length SARA and the SARA peptide correlate. There is a positive correlation, not predicted by any prior studies, that a similar pattern of Smad3 hot-spots are involved in
binding to both the SKI peptide and the SIP1 peptide. In contrast, there are significant negative correlations between Smad3 mutants binding to SARA versus Smurf2
peptide as well as between Smad3 mutants binding to Smad4 versus SARA peptide. The analysis also was used to correlate the protein binding properties of the hot
spot mutations (LUMIER assay in 293 cells, Tables 2 and 3) to function (reporter gene assay in JEG3 cells, Figure 2). As expected, rescue of the Smad3-dependent reporter
gene activation correlated with binding to Smad4. Rescue also significantly correlated with how the hot-spot mutations affected binding to the SIP1 peptide or SKI274E.
In contrast, rescue of the reporter gene did not correlate with how the Smad3 mutant hot-spots affected binding to Smurf2 peptide or to SARA.
doi:10.1371/journal.pone.0025021.t004
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and standard curves as described in the Materials and Methods
(Figure 3). The expression levels of myc-Smad3 variants relative to
beta-tubulin expression levels were generally lower than the wild-
type myc-Smad3 expression in the C2C12 populations although at
least one replicate cell population for each variant was within
three-fold of the wild-type Smad3/beta-tubulin ratios of 1.0 (A)
and 0.7 (B).
Several candidate Smad3-induced genes were identified from
the literature or identified on gene arrays with mRNA from TGF-
b-treated C2C12 cells infected with the retrovirus expressing wild-
type Smad3 (see Materials and Methods); changes in gene
expression were confirmed using RT-PCR (Figure 4). Several
genes showed increased basal expression with addition of the
exogenous Smad3 from the retroviral infection and an additional
increase upon treatment with TGF-b for 24 hours. Note, for
example, the brighter band intensity for Adamts4 with addition of
exogenous Smad3 and the further increase in brightness with
TGF-b treatment (Figure 4). We also identified three genes whose
expression was decreased by the addition of exogenous Smad3 and
TGF-b treatment in C2C12 cells: Cst6, Myl1 and Sgcg (Figure 4).
The effect of the Smad3 mutations on the TGF-b-induced
expression of six of these genes in C2C12 cells was examined by
quantitative RT-PCR (Q-RT-PCR). Expression levels of each
gene were normalized to beta-Actin mRNA and compared to
levels in C2C12 cells infected with either retrovirus that did not
encode Smad3 (Empty vector, EV) or retrovirus expressing the
myc-tagged wild-type Smad3. Over-expression of the wild-type
Smad3 in the C2C12 cells increased the basal expression levels of
the genes even in the absence of TGF-b, but all of the genes
exhibited further increases upon exposure to TGF-b for 24 hours.
For example, the wild-type Smad3 expression in two independent
replicates of infected C2C12 cells increased the basal and TGF-b-
induced expression of Mmp9 over cells infected with the control
EV retrovirus (Figure 5). In contrast, C2C12 cells expressing the
D408H variant of Smad3, which had reduced binding to Smad4
(Table 2) and reduced rescue of the TGF-b-induced reporter gene
in JEG-3 cells (Figure 2), had basal and induced levels similar to
the EV control cells (Figure 5), even though Smad3 D408H was
expressed at about two-fold higher levels than the wild-type myc-
Smad3 protein (Figure 3). Although the replicate cell populations
expressing the Smad3 mutants varied in their Mmp9 expression
relative to beta-actin by two-fold or more in some cases, the trends
were consistent between the replicates. The Smad3 mutants Del-
PPGY, W326A, and K341A had basal and induced levels similar
to wild-type Smad3, whereas V356R and W406A had a reduction
in the TGF-b-induced level of Mmp9 (Figure 5). Smad3 E267A
and Y226A primarily induced elevated basal levels of Mmp9
(Figure 5). The corresponding analyses for the other five genes,
Il11, Tnfaip6, Fermt1, Olfm2 and Wnt11, are shown in the Figure
S1A–E.
To compare how each mutation affected the TGF-b inducibility
of the six genes, the fold increase over basal expression induced by
TGF-b treatment for 24 hours was calculated and normalized as
the percent of the fold induction mediated by wild-type Smad3
(Table 5). This data was subjected to a cluster analysis (Figure 6).
The PPGY deletion and Smad3 K341A variants were similar to
wild-type Smad3 in mediating TGF-b inducibility except for the
reduced TGF-b inducibility of Olfm2 with Smad3 K341A. Smad3
W406A, V356R, E267A and Y226A clustered together because
Figure 3. Comparable expression levels of wild-type myc-Smad3 and myc-Smad3 variants in infected C2C12 cell populations. Cell
lysates were prepared from two independent sets (A and B) of C2C12 cell populations independently infected with retrovirus encoding wild-type
myc-Smad3 (blots on the left) and either mutant myc-Smad3 genes or retrovirus without the myc-Smad3 gene (Empty Vector, EV, blots on the right).
The lysate proteins were resolved by SDS-PAGE. Western blots were probed with anti-myc antibody and IRDye goat anti-mouse 800 secondary
antibody, as well as anti-beta-Tubulin antibody and IRDye goat anti-rabbit 680 secondary antibody and imaged on an Odyssey IR scanner. Titrations
of wild-type Smad3 lysates from both infections were analyzed two times (left-top and left-bottom of figure) and were used to generate a standard
curve. Total lysate protein (2.5 mg) was loaded for lysates from cells infected with EV or mutant Smad3 retroviruses with the exception of K341A
(1.25 mg, lane 20, infection B). The lack of signal in the EV cell lysates loaded in lane 10 of each gel indicates that the signal being detected is myc-
Smad3. The ratio represents the expression of myc-Smad3 relative to the beta-Tubulin loading control. The ‘‘Infection A’’ set had expression of
mutant Smad3’s within a ten-fold range of wild-type myc-Smad3; the ‘‘infection B’’ set had expression of mutant Smad3’s within a three-fold range of
wild-type myc-Smad3. The Smad3 D408H mutation (lane 11) consistently had the highest levels of Smad3 protein expression.
doi:10.1371/journal.pone.0025021.g003
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mediated by wild-type Smad3. However, the gene expression
data in Figure 5 and Figure S1 reveal that the reduced TGF-b
inducibility occurs by different mechanisms, with V356R and
W406A reducing the TGF-b-induced levels and E267A and
Y226A increasing the basal levels of gene expression. Note that
W406 and V356 are located in the same region of the
hydrophobic corridor on Smad3, whereas E267 and Y226 are
located in a different region on the surface of Smad3 (Figure 1B).
The mutations in the portion of the hydrophobic corridor near the
alpha-helix 2, W326A, Q322A/Y324A, also clustered as having
intermediate reductions in the levels of expression for the six genes
examined with minimal effects on Mmp9 (Figure 6; Table 5). The
Y297A mutation was unique in the cluster analysis; it enhanced
the TGF-b inducibility of five of the six genes because it exhibited
lower basal levels of gene expression than wild-type Smad3.
Discussion
We have reported on some protein binding defects and gene
expression changes caused by the mutation of specific amino acids
on the surface of Smad3. As these amino acids are conserved in
Smad2, the corresponding mutations in Smad2 might also affect
Smad2 function, but Smad2 was not examined in these studies.
The protein ligands used to query the binding properties of the
Smad3 variants were a small subset of the identified Smad3-
interacting proteins. They were used to reveal whether a mutation
in a putative hot-spot on Smad3 reduced the binding to one or
more proteins and, importantly, retained the binding to other
Smad-binding partners, i.e., that each Smad3 mutation only
affected binding to a portion of this test set of protein and peptide
ligands. Although the test set was meant to represent the larger
(.50) group of known Smad3-interacting proteins and was large
enough to characterize selective protein-binding deficits in the
variants, the test set of proteins and peptides cannot reveal the full
extent of the protein-binding defects or which other Smad3
protein-protein interactions may be reduced by a specific
mutation. As such, the effects of the mutations on the
transcriptional functions of Smad3 are very likely mediated by
other Smad3-interacting proteins that were not in the test panel.
Therefore, one should not conclude that any of the specific protein
ligands used in the reported binding studies are directly implicated
in mediating the reported gene expression changes. One exception
to this caveat may be the mutations that reduce binding to Smad4.
Figure 4. Smad3 and TGF-b alter the levels of gene expression in C2C12 cells. C2C12 cell populations infected with retrovirus without the
myc-Smad3 gene (Empty Vector, EV) or retrovirus encoding wild-type Smad3 were treated with either 1 mM SB431542 or 100 pM TGF-b for 24 hours
before RNA isolation. The 16 genes were amplified by RT-PCR using the primer sets shown in Table S3. The annealing temperature and number of
cycles of PCR were optimized for each primer set. The overexpression of Smad3 had modest effects on the levels of some genes (Adamts4, Cst6,
Pdgfb, Pai1 and Wnt11) but had detectable effects on the levels of other genes (Fermt1, Gfpt2, Il11, Mmp9, Myl1, Npy, Olfm2, Sgcg). The expression
levels of three genes, Cst6, Myl1 and Sgcg, were decreased by TGF-btreatment. Overexpression of Smad3 caused further reductions in the levels of
Myl1 and Sgcg.
doi:10.1371/journal.pone.0025021.g004
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form a heterotrimer with Smad4 that accumulates in the nucleus,
reduced Smad4 binding is likely to be in part responsible for the
reduced activity of these mutations in reconstituting Smad3-
dependent reporter gene activity in JEG-3 cells.
The protein binding properties of the Smad3 variants were
quantified in a modified version of the LUMIER assay [48].
Proteins were co-expressed in HEK-293 cells with an activated
Alk5 receptor to constitutively phosphorylate Smad3. All of the
previously described Smad3 mutations exhibited the same defects
in protein binding in this assay as had been initially reported using
other assay methods. By using a larger panel of Smad3-binding
proteins and peptides, we identified additional binding interactions
that were impaired by each mutation and also demonstrated that
other binding interactions were not affected under the conditions
of the assay. In the cases where both a Smad binding domain and
the corresponding full length protein were tested, the full length
protein always provided more binding to the Smad3 variant. The
increased binding by the full length protein may indicate that the
Smad binding domain is in a more optimal conformation in the
native protein than on the Trx scaffold or that the full length
protein has other motifs that contribute to the binding in addition
to the motif displayed on the Trx scaffold. In either case, full-
length Smad-binding proteins will be a better indicator in future
studies of the consequences of a hot-spot mutation in cells.
The binding assays revealed several examples where the amount
of binding between a Smad3 variant and a Smad-binding protein
was greater than with the wild-type Smad3 protein. For example,
more Renilla-Smad3 E267A was pulled-down with Smad4, Smad3
and theSmad-bindingdomainsofSmurf2andSki.Greater amounts
of Renilla luciferase Smad3 V224A were pulled-down with
SkiW274E and the Smad-binding domains from Smurf2, Ski and
SIP1, but not by Smad3 or Smad4. The Smurf2 Smad binding
domain pulled down more of nine different Renilla-Smad3 variants
in Table 3. Previous studies have reported a propensity for mutant
Smad proteins to undergo degradation, which would be consistent
with increased interactions with an E3 ubiquitin ligase such as
Smurf2 [66]. The molecular mechanism(s) for the increased binding
in the present studies are not known. The mutations may enhance
the binding affinity between Smad3 and a Smad-binding protein
either by improving the binding interface directly or by altering the
conformation of Smad3 to improve the binding interface. An
alternative explanation is that these mutations reduce the amount of
some Smad3-binding proteins interacting with Smad3, thereby
making more Smad3 available to interact with other Smad3-binding
proteins. Independent of the mechanism, the results indicate that the
functional consequences of perturbing a protein-binding hot-spot on
a hub protein by mutation or with a small molecule ligand or drug
may be the result of both decreased interactions with some protein
ligands and also increased interactions with other protein ligands.
For example, the Smad3 E267A protein exhibited increased binding
to several protein ligands and mediated increased basal levelsof gene
expression and wild-type (or greater than wild-type) TGF-b-induced
levels of gene expression on several of the genes examined in C2C12
cells. This high basal activity resulted in a lower fold-induction by
TGF-b, as indicated by the lower TGF-b inducibility in Table 5 and
Figure 6. The increase in basal gene expression by Smad3 E267A
was not due to it being expressed at higher levels of protein
expressionthantheexogenouswild-typeSmad3ortheothervariants
(Figure 3). In future studies on the functional deficits of Smad3
variants it will be important to examine both the loss of binding
partners and the increase of other Smad3-binding proteins in the
regulatory complex relative to the components of the wild-type
Smad3 regulatory complex.
Figure 5. TGF-b induced Mmp9 expression levels are increased by exogenous wild-type Smad3 and some Smad3 variants in C2C12
cells. RNA was isolated from cell lysates prepared from two independent sets (A and B) of C2C12 cell populations independently infected with
retrovirus without the myc-Smad3 gene (EV) or retrovirus encoding wild-type or mutant Smad3s. The C2C12 cell populations had been exposed to
either 1 mM SB431542 or 100 pM TGF-b for 24 hours before RNA isolation. Mmp9 and beta-actin mRNA expression levels were detected by
quantitative RT-PCR in three replicate wells and the MMP9 levels were normalized to the level of beta-actin in each cell lysate. TGF-b increased the
expression levels of MMP9 in all of the cell lysates. Expression of wild-type Smad3 increased the basal expression and induced expression levels of
Mmp9 five-ten fold over the levels in the cells infected with the EV retrovirus. Expression of Smad3 D408H did not increase the basal expression or
induced levels compared to cells infected with the EV retrovirus. Some other Smad3 mutants affected either the basal or induced expression levels
(summarized in Table 5). The numerical values indicating the heights of the bars are only shown if the value is .1. The error bars indicate the
standard deviations of the three replicate wells of Q-RT-PCR reactions run on each RNA preparation. While the levels of Mmp9 expression differed
between the A and B cell populations for some of the mutants, the rank orders across the set of mutants were highly correlated. For SB431542
treated cells, Kendall’s rank correlation coefficient (tau) for the A and B cell populations was 0.58 (P=0.006), and that for TGF-beta treated cells was
0.61 (P=0.006).
doi:10.1371/journal.pone.0025021.g005
Protein-Binding Hot-Spot Mutations on Smad3
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25021Although only a small panel of Smad3-reponsive genes was
examined, there was some evidence for different hot-spot
mutations causing distinct effects on gene expression. For example,
the Y297A mutation, decreased binding to SARA and Ski
(Table 3) and MEF2C and the Smad binding domain from
FoxO3 (Table S1) but provided 100% reconstitution of the
Smad3-dependent reporter gene activation in JEG-3 cells
(Figure 2). However, Smad3 Y297A also had the unique property
among the mutations examined of enhancing the TGF-b
induciblity of five of the endogenous genes tested in C2C12 cells.
Overexpression of wild-type Smad3 is well-known to induce gene
expression changes in the absence of TGF-b, but the Smad3
Y297A variant induced lower levels of expression in the absence of
TGF-b than did wild-type Smad3, resulting in a greater fold
induction when TGF-b was added.
Another example for a selective effect was observed with Smad3
K341A. The K341A mutation decreased binding to SARA and
Ski (Table 3) and the Smad binding peptide from CBP (Table S1)
and provided less than 50% reconstitution of the Smad3-
dependent reporter gene activation in JEG-3 cells (Figure 2), but
it mediated TGF-b inducibility similar to wild-type Smad3 for five
of six endogenous genes tested. Interestingly, it was compromised
by almost 50% for mediating TGF-b activation of Olfm2.
Examination of a larger panel of Smad3 responsive genes and
expression of the Smad3 K341A protein in an otherwise Smad3-
deficient cell line may identify genes with an even greater
dependence than Olfm2 on K341 in Smad3.
Several genes were identified from a gene array analysis of
mRNAs from the TGF-b-induced C2C12 cells over-expressing
wild-type Smad3 versus TGF-b-induced C2C12 cells infected with
the control retrovirus that did not encode Smad3 (empty vector,
EV). RT-PCR analysis confirmed the increased level of expression
for thirteen genes and a reduced level of expression for three genes
after 24 hours of TGF-b treatment; in most cases the responses
were amplified by the overexpression of wild-type Smad3.
Although we did not select for any particular functionality, most
of the genes with increased expression levels encode proteins with
roles in cell signaling, cell adhesion or extracellular matrix
modifications. Several of the genes including Pai1, Mmp9 and
Il11 have been identified as TGF-b-responsive genes in many
other studies and cell-types. For example, Pai1 is induced by TGF-
b in muscle satellite cells [67] and MMP9 is an important Smad3
target in the process of cancer cell invasion [28]. Regulation of
Il11 by TGF-b signaling is important for metastasis to bone of
breast and melanoma cancer cells [68,69,70]. Pai1 and Cst6 were
identified as direct targets for Smad3 regulation in a genome wide
chromatin immunoprecipitation study [71]. Cst6 encodes cystatin
M/E, an inhibitor of the cathepsin L cysteine protease, which has
Table 5. Mutations on Smad3 have differential effects on the TGF-b inducibility of six endogenous genes in C2C12 myoblasts.
Smad3 Mutants Percent of the TGF-b inducibility provided by wild-type Smad3
Mmp9 Il-11 Tnfaip6 Fermt1 Olfm2 Wnt11
Wild-type (A) 100 (14) 100 (18) 100 (25) 100 (16) 100 (29) 100 (13)
Wild-type (B) 100 (27) 100 (28) 100 (25) 100 (38) 100 (59) 100 (31)
Del-PPGY (A) 106 (14) 55 (8) 82 (30) 114 (23) 144 (95*) 163 (40*)
Del-PPGY (B) 113 (29) 131 (41*) 84 (24) 93 (27) 145 (65*) 115 (39*)
Q322A/Y324A (A) 102 (19) 24 (4) 39 (11) 71 (24) 44 (11) 57 (11)
Q322A/Y324A (B) 130 (31) 37 (10) 29 (19) 35 (13) 43 (19) 46 (18)
W326A (A) 66 (14) 20 (3) 54 (11) 42 (5) 72 (23) 56 (7)
W326A (B) 186 (68) 56 (13) 49 (28) 72 (24) 40 (18) 42 (11)
K341A (A) 202 (38) 80 (14) 104 (25) 137 (70*) 63 (34*) 105 (21)
K341A (B) 103 (25) 109 (23) 117 (27) 85 (59*) 56 (45*) 77 (28)
E267A (A) 27 (3) 20 (3) 25 (5) 32 (5) 29 (6) 46 (9)
E267A (B) 43 (11) 53 (14) 36 (19) 36 (14) 19 (8) 33 (9)
Y297A (A) 103 (19) 80 (14) 199 (78*) 245 (53*) 130 (34*) 266 (114*)
Y297A (B) 198 (69*) 73 (39*) 178 (42*) 314 (127*) 204 (226*) 154 (50*)
Y226A (A) 35 (5) 13 (2) 18 (4) 31 (6) 16 (4) 33 (5)
Y226A (B) 54 (12) 21 (5) 21 (5) 41 (14) 22 (9) 39 (10)
V356R (A) 52 (6) 10 (1) 16 (3) 29 (8) 17 (5) 20 (3)
V356R (B) 49 (15) 10 (2) 17 (4) 22 (10) 13 (11) 17 (5)
W406A (A) 50 (8) 12 (2) 19 (4) 26 (5) 17 (5) 22 (4)
W406A (B) 33 (10) 13 (3) 19 (4) 24 (9) 16 (9) 18 (4)
Populations of C2C12 cells from two independent infections (A and B) with retroviruses expressing wild-type or mutant Smad3s were treated with 100 pM TGF-b1
(induced) or the TGF-b-receptor kinase inhibitor SB431542 (basal) for 24 hours. Quantitative-RT-PCR was used to quantify the levels of the six indicated gene products
and these were normalized to the level of beta-actin mRNA in each lysate. The normalized levels for both the basal and induced cell lysates are shown in Figure 5 and
Figure S1. TGF-b inducibility, or fold increase over basal level, was calculated as the ratio of the TGF-b-induced level divided by the basal level of expression. In the
C2C12 cells infected with retrovirus expressing wild-type Smad3 (both the A and B infections), the fold increases over basal induced by TGF-b were: MMP9 661; Il-11
3165; Tnfaip6 1162; Fermt1 862; Olfm2 31610; Wnt11 1262. The TGF-b inducibility provided by the mutant Smad3 proteins was normalized to the TGF-b inducibility
provided by wild-type Smad3 in the infected cells which was set to 100%. The standard deviations are indicated in parenthesis.
*Variance in the very low basal expression levels were the primary contributors to the large standard deviation.
doi:10.1371/journal.pone.0025021.t005
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sion [72]. Methylation or loss of cystatin M/E expression has been
reported in breast [73] and prostate cancers [74]. To the best of
our knowledge Cst6 expression has not previously been reported
in myoblasts.
The two other genes whose expression levels were reduced in
the C2C12 cells were Myl1 and Sarcoglycan, Sgcg. Myl1 has been
associated with muscle cell differentiation and knock-down of its
expression enhanced myoblast proliferation [75]. Sgcg mutations
cause limb-girdle muscular dystrophy and Smad3 has been
implicated in preventing inappropriate activation of Sgcg gene
expression during myogenic differentiation [76]. The reduced
levels of Myl1 and Sgcg are consistent with the inhibition of
muscle differentiation by TGF-b and Smad3. One of the earliest
cellular responses reported for TGF-b was inhibition of myoblast
differentiation in culture [77,78]. Smad3 binds directly to the
MyoD bHLH domain to block MyoD/E protein dimerization and
DNA binding [60] and to the myogenic transcription factor MEF2
to prevent muscle-specific gene expression [61]. Persistent TGF-b
expression contributes to the muscle fibrosis and loss of muscle
function in neuromuscular diseases such as Duchenne muscular
dystrophy [79,80].
Fermt1 encodes Kindlin-1, a focal adhesion protein involved in
cytoskeletal interactions and implicated in integrin beta-1
activation [81,82]. Loss-of-function of Fermt1 is associated with
Kindler syndrome, an autosomal recessive disorder characterized
by skin atrophy and blistering [83]. Kindlin-1 is a member of a
family of proteins that are key regulators of cell-matrix interactions
[84]. Tnfaip6 or TGS-6 (tumor necrosis factor, alpha-induced
protein 6) encodes a hyaladherin, a hyaluronan-binding protein,
and is involved in extracellular matrix stability and cell migration
[85]. TGS-6 expression is induced by TGF-b in dermal fibroblasts
and is a required mediator of the TGF-b induced fibroblast-
myofibroblast transition in wound healing [86,87]. Olfm2 or
olfactomedin 2 is a secreted glycoprotein belonging to a family of
related olfactomedins [88]. We are not aware of previous reports
of a role for olfactomedins in muscle or myoblasts. A related family
member, Olfm1, has been reported as a modulator of Wnt
signaling in zebrafish [89]. The Wnt family member that was
induced in the studies reported here, Wnt11, has been implicated
in fostering cell adhesion of cardiomyocytes essential for proper
heart development [90].
Understanding the multiple functions of hub proteins requires
new approaches. Knockdown approaches or knock-out mutations
do not allow analysis of the distinct roles of a hub protein.
Mutations in protein-binding hot-spots have the potential to only
perturb a subset of the total binding interactions, providing an
opportunity to learn the biological significance of those interac-
tions. This approach is analogous to the generation of an allelic
series of mutations in classical genetics for the purpose of revealing
the different developmental roles of a specific gene. Future studies
will benefit from a more comprehensive analysis of the gene
expression changes caused by each hot-spot mutation, from
analysis of the biological consequences on cellular phenotypes such
as proliferation, differentiation, or pathological functions and from
characterization of the changes in the composition of the protein
complexes formed on the hub protein in the same cell-type and
cell context being studied for phenotypic changes.
Materials and Methods
Cell lines and cDNA clones
JEG-3, HEK-293, and C2C12, cells were obtained from the
American Type Culture Collection (HTB-36, CRL-1573, CRL-
Figure 6. Heat map of gene activation in wild-type and mutant Smad3-expressing C2C12 cells. Expression levels are shown as a
percentage of wild-type expression after averaging duplicates. Genes and cells are ordered according to average-linkage hierarchical clustering,a s
implemented in the heatmap.2 function in the gplots R package [98].
doi:10.1371/journal.pone.0025021.g006
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5% CO2. JEG-3 cells were maintained in MEM (Modified
Essential Medium), and supplemented with 10% fetal bovine
serum (FBS) (Gibco, Invitrogen, Carlsbad, CA). HEK-293 cells
were grown in DMEM (Dulbecco’s Modified Eagle Medium,
Gibco, Invitrogen) supplemented with 5% FBS and the murine
C2C12 cells were grown in DMEM supplemented with 10% FBS.
The following plasmids were generously provided by the
indicated individuals: pcDNA3-ALK5, Carl-Henrik Heldin (Lud-
wig Institute for Cancer Research, Uppsala, Sweden); pME-Flag-
ATF3, Shigetaka Kitajima (Tokyo Medical and Dental University
Tokyo, Japan); pCS2-Flag-mAxin, Xi He (Children’s Hospital
Boston, Boston MA); pCMV5-Flag-FoxO3, Smad4, Smad3,
Smad3-V356R, Smad3-Y297A, Smad3-K341A, Smad3-K340A,
Smad3-C338A, Joan Massague ´ (Sloan Kettering Cancer Center,
New York, NY); pCMV-Flag-hHNF4alpha, Paul Kuo (Duke
University Medical Center Durham, NC); HA-SRF, John Lough
(Medical College of Wisconsin, Milwaukee, WI); pcDNA3-Flag-
hMEF2C(1-302), Zhenguo Wu (Hong Kong University of Science
& Technology, Clear Water Bay, NT, Hong Kong); CMV10-
3XFlag-Myo-D, Jin Cheng (H. Lee Moffitt Cancer Center and
Research Insitute, Tampa, FL); pcDNA3-Flag-Smad3(STSVL/
NKN), Kohei Miyazono (University of Tokyo, Tokyo, Japan);
SBE12-luciferase, Peter ten Dijke (Leiden University Medical
Center, Leiden, Netherlands); pCMV5b-Flag-SkiW274E, Kunxin
Luo (University of California, Berkeley, CA); pACT2-SIP1-315-
487, Danny Huylebroeck (Flanders Institute for Biotechnology,
Leuven, Belgium), pCMV5b-Flag-SARA (Addgene plasmid
11738) and pCMV5-hRLuc-Smad3, Jeffrey Wrana (Samuel
Lunenfeld Research Institute, Mount Sinai Hospital,Toronto,
Canada).
The following Smad binding domains were isolated by PCR
and cloned into the pCI-3xFLAG-Trx plasmid using a unique
RsrII site: CBP amino acids 1940–1998 [31,49], xFoxH1 amino
acids 293–317 [44,49], SRF amino acids 132–223 [91], ATF3
amino acids 61–111 [92], FoxO3 amino acids 153–249 [93],
SARA amino acids 665–721 [32,51], Ski amino acids 2–56 [22],
and SIP1 amino acids 315–487 [94].
Smad3 Mutants
Mutations were created using site directed mutagenesis [95].
Smad3 mutations were created in the Renilla luciferase pCMV5-
hRLuc Smad3 using PfuUltraII Fusion hot-start DNA polymerase
(Stratagene, La Jolla, CA). Mutations were verified by sequence
analysis of the entire expression construct at the University of
Wisconsin Biotechnology Center. Mutated Smad3 genes were
digested with restriction endonucleases and inserted into the
pCMV5 3xmyc-Smad3 vector or the pCMMV-IRES-GFP 3xmyc
vector.
Retrovirus Production and Infection
To generate retroviruses, HEK-293 cells were plated at 1610
6
cells in a 10 cm dish and transfected 24 hours later with a
pCMMV-IRES-GFPvector [96] containing either no insert
(empty vector, EV), wild-type Smad3 (WTSmad3), or mutant
Smad3 (5 mg DNA per plate) as well as three plasmids encoding
vesicular stomatitis virus G protein (VSVG) (0.5 mg DNA per
plate), gag/pol elements (1.5 mg DNA per plate), and NFkB (0.5 m
per plate) using the TransIT-LT1 Transfection Reagent (Mirus Bio
LLC, Madison, WI) at a transfection reagent to DNA ratio of 3:1.
Cells were incubated overnight at 37uC, 5% CO2. Media with
transfection reagent was removed and replaced with DMEM
containing 5% FBS with 50 mM HEPES. Supernatants were
collected at 48 and 72 hours. Supernatants were centrifuged at
1500 rpm for 10 minutes at 4uC and filtered through 0.2 mm
filters. Filtered supernatants were centrifuged at 20,000 rpm for
two hours at 4uC. Virus pellets were resuspended in DMEM
containing 5% FBS with 50 mM HEPES and stored at 280uC.
For infection, C2C12 cells were plated at 1610
5 cells in a 6 cm
dish and infected the following day with a total volume of 1.2 ml of
10 mg/ml polybrene and 40–175 ml of concentrated retroviruses in
DMEM containing 10% FBS at 4uC with rocking for one hour.
Then, 3 ml of DMEM containing 10% FBS was added to each
plate and incubated overnight at 37uC, 5% CO2. Cells were
allowed to propagate for no longer than one week before
experimental analysis. The infection process was repeated twice
for each mutant.
Luminescence-based mammalian interactome mapping
(LUMIER) assay
This is a modification of the assay originally described by Dr.
Jeffery Wrana and colleagues [48]. HEK-293 cells were seeded in
12 well plates and transfected with pCMV-hRLuc Smad3 wild-
type or variants (0.2 ug/well), Flag-tagged Smad binding partner
(see cell lines and cDNA clones section) (0.2 ug/well), and a
plasmid expressing the constitutively active form of the type I
receptor, Alk5 (0.15 ug/well) using TransIT-LT1 transfection
reagent (Mirus Bio LLC). Cells were incubated for 24 hours
before harvesting. White 96-well anti-Flag coated plates were
prepared by binding 0.008 mg anti-Flag antibody (A8592, Sigma)
to Reacti-bind protein G coupled plates (Pierce, Thermo,
Rockford IL) at 4uC for one hour, according to the plate
manufacturer’s instructions. Transfected cells were lysed on ice for
15 minutes in 200 ml TNE lysis buffer: 10 mM Tris-HCl pH 7.8,
150 mM NaCl, 1 mM EDTA, 1% Igepal CA-630 (Sigma-Aldrich,
St. Louis, MO), and Roche complete mini protease inhibitor
(Roche, Indianapolis, IN). The debris was pelleted out of the
lysates by centrifugation at 14,000 rpm for 12 minutes at 4uC and
the cleared lysates were added to the anti-Flag coated plates. The
plate was incubated for two hours at 4uC with gentle vortexing and
washed with 0.05% Tween-20 Tris-buffered saline four times.
Renilla luciferase activity was measured with the Dual-Glo Assay
system (Promega,Madison, WI) as follows: 20 ml of serum free-
Dulbecco’s Modified Eagle Medium (DMEM) was added to each
well of the plate followed by 20 ml of Dual-Glo Luciferase Buffer
(this buffer is used without firefly-luciferase substrate added for the
purpose of maintaining proper buffer composition for the Renilla-
Luciferase substrate). Immediately prior to analyzing the plate,
20 ml of Dual-Glo Stop-N-Glo buffer containing Renilla-Lucifer-
ase substrate was added to each well. The plate was analyzed on a
PerkinElmer Wallac 1420 Victor Plate Reader which measured
relative light units in each well. As a transfection control, 5 mlo f
debris-free lysate was analyzed for the total Renilla luciferase
activity as described above, using 5 ml each of serum free-DMEM,
Dual-Glo Luciferase Buffer and Dual-Glo Stop-N-Glo/Renilla
substrate. A pCI-3xFlag-TrxGA construct, which consists of a
tandem repeat of glycine and alanine and does not bind to Smad3
[49], was used as a control in every experiment to determine the
level of background non-specific luciferase binding. The back-
ground signal obtained with TrxGA was subtracted from each
sample and the data for each Smad3 mutant was normalized to
wild-type Smad3 Renilla levels and shown as a percent.
Reporter gene assay
For rescue experiments in the JEG-3 cell line, 3610
5 cells per
well were seeded in 24-well plates and allowed to adhere
overnight. Cells were transfected with appropriate plasmids using
TransIT-LT1 transfection reagent (Mirus Bio) at a transfection
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SBE12-luc reporter gene [97] (10 ng per well), a reporter plasmid
encoding CMV-b-galactosidase (b-gal) (10 ng per well), pCMV5
Renilla luciferase Smad3 (20 ng per well). An empty vector pCI
plasmid was used to normalize the amount of DNA transfected to
a total of 100 ng per well. Eight to 12 hours after transfection,
media was removed and replaced with 100 pM TGF-b (R & D
Systems, Minneapolis, MN). Twelve hours after TGF-b treatment,
cells were washed with phosphate buffered saline (PBS) and lysed
with 75 ml of lysis buffer (Galacto-Star kit, Applied Biosystems,
Invitrogen, Carlsbad, CA) for 15 minutes. b-galactosidase activity
was measured using 5 ml of cell lysate plus 100 ml of Galacto-Star
b-gal substrate. Luciferase activity was measured with 50 ml of cell
lysate plus 50 ml of Bright-Glo luciferase substrate (Promega) and
Renilla-luciferase was measured with 5 ml of cell lysate (Dual-Glo
Luciferase kit, Promega). b-galactosidase values were used for
normalization of the luciferase value. Data in each experiment are
shown as the mean 6 standard deviation.
Quantitative Western for Myc-Smad3 expression
Stable C2C12 cells were treated with 1 mM SB431542 (Tocris
Bioscience, Ellisville, MO) or 100 pM TGF-b for 24 hours prior to
lysis in TNE lysis buffer, and Roche complete mini protease
inhibitor at 4uC. Lysates were cleared of debris by centrifugation at
14,000 rpm for 12 minutes at 4uC and proteins were separated by
SDS-PAGE in4–20% gradient midi gels (NuSep, Lane Cove, NSW
Austrailia) and transferred to low background fluorescence
membrane, Immobilon F PVDF (Millipore, Billerica, MA). A 1:2
solution of PBS and Seablock (Pierce, Thermo) was used for
blocking and antibody dilution. Primary antibodies, 0.4 mg/ml
mouse monoclonal IgG1 cMyc 9E10 (Santa Cruz SC-40, Santa
Cruz, CA)and 1.2 mg/ml rabbitpolyclonal to beta Tubulin(Abcam
ab6064) were applied overnight at 4uC. LI-COR (Lincoln, NE)
IRDye secondary antibodies were subsequently applied; 67 ng/ml
Goat anti-Mouse IRDye 800 CW (LI-COR, 827-08364) and
67 ng/ml Goat anti-Rabbit IRDye 680 (LI-COR, 926-32221) for
one hour at room temperature. Blots were imaged on the LI-COR
Odyssey Infrared Imaging System. Myc-Smad3 protein expression
was quantified relative to beta-Tubulin, as follows: a two-fold
dilution series of wild-type Smad3 cell lysate, from 0.31 mgt o
5.0 mg, and 2.5 mg mutant Smad3 cell lysates were compared. The
Odyssey 3.0 analysis software was used to estimate the integrated
intensity of each myc-Smad3 and beta-Tubulin band. Standard
curves of both myc-Smad3 and beta-Tublin were generated from
thetwo-folddilutionseriesofwild-type Smad3.Thestandard curves
were used to convert each integrated intensity to a total protein
value and the total protein value for each myc-Smad3 was divided
by the total protein value for the beta-Tubulin from the same
sample to normalize for differences in sample loading.
RNA isolation, RT-PCR and Q-RT-PCR Methods
RNA was isolated from C2C12 cells plated in 10 cm dishes
treated with either 1 mM SB431542 or 100 pM TGF-b using the
RNeasy Plus kit (Qiagen, Valencia, CA). Quantification of RNA
was done using a Nanodrop spectrometer and 1 mg of RNA was
used for a single cDNA reaction (Superscript II, Invitrogen) along
with oligodT primers following the manufacturer’s protocol.
The expression of the following genes were quantified by RT-
PCR or Q-RT-PCR: Beta-Actin (NM_007393); Pai1, Serpine 1
(NM_008871); Cst6, cystatin E/M (NM_028623); Mmp9, matrix
metallopeptidase 9 (NM_013599); Il11, interleukin 11
(NM_008350); Tnfaip6, tumor necrosis factor alpha induced
protein 6 (NM_009398); Fermt1, fermitin family homolog 1
(NM_198029); Oflm1, olfactomedin 1 (NM_173777); Wnt11,
wingless-related MMTV integration site 11 (NM_009519);
Adamts4, a disintegrin-like and metallopeptidase with thrombos-
pondin type 1 motif 4 (NM_172845); Clu, clusterin (NM_013492);
Edn1, Endothelin 1 (NM_010104); Gfpt2, glutamine fructose-6-
phosphate transaminase 2 (NM_013529); Myl1, myosin light
polypeptide 1 (NM_021285); Npy, neuropeptide Y (NM_023456);
Pdgfb, platelet derived growth factor, B polypeptide
(NM_011057); Sgcg, sarcoglycan, gamma (NM_011892) (see
Table S3 for primer and probe sequences).
RT-PCR was performed using 1 ml of undiluted cDNA, 0.2 mM
of forward and reverse primers, and Go Taq Green Master Mix
26(Promega) at a final concentration of 16. The RT-PCR was
run in a thermocycler with the following program: 95uC for
3 minutes; 30 or 35 cycles of 95uC for 30 seconds, 58uC for
45 seconds, 72uC for 1 minute; 72uC for 8 minutes. RT-PCR
products were run on a 2% agarose gel with ethidium bromide
and imaged using a gel documentation system (BioRad, Hercules,
CA).
For Q-RT-PCR reactions, cDNA was diluted 1:4 with water and
reactions were set up in triplicate. The Q-RT-PCR was conducted
with 500 nM of forward and reverse primers (UW Biotechnology
Center) and 200 nM FAM-labeled probes with an internal ZEN
quencher and 39 Iowa Black quencher (PrimeTime QPCR probes,
Integrated DNA Technologies, Coralville, CA) in a 20 mlr e a c t i o ns e t
up in 384-well plates (Applied Biosystems). AmpliTaq Gold PCR
master mix (Applied Biosystems) was used at 16in all experiments. All
experiments were run on the ABI 7900HT using the standard thermo
cycling protocol. Data were analyzed based on a standard curve which
was performed for each gene in every experiment. A pool of cDNA
from empty vector and wild-type Smad3- expressing cells treated with
either 1 mM SB431542 or 100 pM TGF-b for 24 hours were used to
generate the standard curves. Relative quantities from 1-0.00521 (a 2-
fold dilution series from 1-1:64 plus 1:192) was used to generate the
standard curve. Controls with no cDNA template added were
conducted for each gene in every experiment. The SDS 2.4 software
(Applied Biosystems) was used to analyze all PCR experiments by
generating a standard curve and estimating the relative quantity of
each unknown sample. The slope of the standard curve for all
experiments was $24. Data were normalized to the relative
expression level of beta-actin, also generated by a standard curve. To
calculate the fold induction, the quantity of each sample after TGF-b
treatment was divided by the quantity of each sample after SB431542
treatment. This was then normalized to the wild-type Smad3 fold
induction as a percentage in Table 5.
Mouse Affymetrix Gene Expression Array Methods
Two biological replicates of RNA samples from each wild-type
Smad3-expressing C2C12 or control (Empty vector) C2C12 cells
treated for 24 hours with 100 pM TGF-b were submitted to the
UW Genome Expression Center for analysis of gene expression
using Affymetrix (Santa Clara, CA) Mouse Gene ST 1.0
microarrays. To identify genes with altered expression between
duplicated empty vector controls and wild-type Smad3, we first
pre-processed the four arrays using robust multiarray averaging as
implemented in the R software package ‘xps’, version 1.10.2
(http://www.bioconductor.org/packages/release/bioc/html/xps.
html). This preprocessing corrects for background noise and array
effects, and aggregates probe data to 28,836 genes. Duplicates
were averaged on the base-2 logarithm scale, and then we took
differences between the averages to obtain logarithm-scale fold
changes. Genes were selected which showed at least a two-fold
change (raw scale) between wild-type and empty vector expressing
cells. Due to the limited sample size, we did not apply any
statistical tests to estimate false-discovery rate. This resulted in 79
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expressing C2C12 cells compared to empty vector cells and 25
genes that were at least two-fold lower in the wild-type Smad3-
expressing cells than the in the empty vector cells. Candidate genes
were selected and expression differences were confirmed using
RT-PCR. All microarray data is MIAME compliant and the raw
data has been deposited in and is available at GEO (http://www.
ncbi.nlm.nih.gov/geo/).
Statistical Analysis
The calculation of standard deviation of the ratios, multiexperi-
ment permutation test, the Spearman’s rank correlation coefficients
and the Kendall’s rank correlation coefficients was done using the
Mstat program (http://www.mcardle.wisc.edu/mstat/). Cluster
analysis of gene expression data was performed according to
average-linkage hierarchical clustering, as implemented in the
heatmap.2 function in the gplots R package [98].
Supporting Information
Figure S1 TGF-b-induced expression levels of five en-
dogenous genes in C2C12 cells are increased by exoge-
nous wild-type Smad3 but different mutant Smad3s
exhibit a variety of alterations in the basal and TGF-b-
induced expression levels. RNA was isolated from cell lysates
prepared from two independent sets (A and B) of C2C12 cell
populations independentlyinfected with retroviruswithout themyc-
Smad3 gene (EV) or retrovirus encoding wild-type or mutant
Smad3s. The C2C12 cell populations had been exposed to either
1 mM SB431542 or 100 pM TGFb for 24 hours before RNA
isolation. Expression levels of beta-actin mRNA and (A) Il11, (B)
Tnfaip6, (C) Fermt1, (D) Olfm2 or (E) Wnt11 were detected by
quantitative RT-PCR in three replicate wells. The expression levels
of the five genes were normalized to the level of beta actin in each
celllysate. Cellsinfected with retrovirusexpressing wild-type Smad3
had higher basal and TGF-b-induced expression levels for all five
genes (panels A–E) than cells infected with the EV retrovirus. In
contrast, cells infected with retrovirus expressing Smad3 D408H
had similar levels of expression to the cells infected with the EV
retrovirus. Other Smad3 mutants affected either the basal or
induced expression levels or both. The numerical values indicating
the heights of the bars are only shown if the value is .1. The error
bars indicate the standard deviations of the three replicate wells of
Q-RT-PCR reactions run on each RNA preparation.
(TIF)
Table S1 Mutations on Smad3 MH2 have differential
effects on interactions with Smad-binding proteins.
Binding between wild-type or mutant Renilla-Smad3 fusion
proteins and nine different Flag epitope-tagged Smad-binding
proteins was quantified by pull-down of protein complexes from
cell lysates and detection of the Renilla luciferase activity per well.
The Renilla luciferase counts were normalized to the number of
counts recovered with phosphorylated wild-type Smad3 (100%).
The proteins were all co-expressed with the constitutively active
Alk5. FL indicates that the full-length protein was used. The
Smad3 MH2 domain has been reported to bind directly to CBP
[99], xFoxH1 [100], MyoD [60], MEF2C [61], Axin [62], Serum
response factor (SRF) [91] and ATF3 [92]. The Smad3 MH1
domain mediates Smad3 binding to Hnf4 [101] and FoxO3 [93].
The amino acids comprising the CBP [31], xFoxH1 [44,100],
SRF [91], ATF3 [92] and FoxO3 [93] Smad3-binding motifs
expressed on the Flag-epitope tagged thioredoxin scaffold are
indicated below each gene. The reduced binding to the Smad
interaction motif from xFoxH1 by mutations in the alpha-helix 2
region of Smad3 (W326A and Q322A/Y324A) is consistent with
previous studies mutating the corresponding amino acids in
Smad2 [44]. Reduced binding to the Smad interaction motif from
CBP by Smad3 W406A also is consistent with a prior study on this
protein interaction that used size exclusion chromatography with
purified proteins [64]. Standard deviations are indicated in
parenthesis. * The Smad3 QPSMT/SE mutant has residues
252–256 and 266–267 changed to the Smad1 equivalent amino
acids (STSVL/NKN) [47].
(DOC)
Table S2 Effects of single alanine mutations in the
Smad3 MH2 region implicated in binding to Ski on
interactions with Smad3-binding proteins. Binding be-
tween wild-type or mutant Renilla-Smad3 fusion proteins and
eight different Flag epitope-tagged Smad-binding proteins was
quantified by pull-down of protein complexes from cell lysates and
detection of the Renilla luciferase activity per well. The Renilla
luciferase counts were normalized to the number of counts
recovered with phosphorylated wild-type Smad3 (100%). The
proteins were co-expressed with the constitutively active Alk5. FL
indicates that the full-length protein was used. The amino acids
comprising the SARA [32], Smurf2 [52], Ski [22], and Sip1 [94]
Smad3-binding motifs expressed on the Flag-epitope tagged
thioredoxin scaffold are indicated below each gene. The reduced
binding by Smad3 with mutations in the QPSMT/SE motifs to
the Ski Smad-binding domain and full length SkiW274E is
consistent with previous studies [47]. The S254A mutation was the
only single amino acid mutation that significantly reduced binding
to the Ski Smad binding domain. Unexpectedly, E267A enhanced
Smad3 interactions with several Smad-binding proteins. Standard
deviations are indicated in parenthesis.
(DOC)
Table S3 Primer and probe sequences used for RT and
Q-RT-PCR. Primer and probe (where applicable) sequences used
for RT and Q-RT-PCR. Probes were labeled with 59 FAM and 39
Iowa Black with an internal ZEN quencher.
(XLS)
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